Home > Zenapax Treatment Evaluations
  • LSK
    Sex: F
    Data Quality: 2 stars
    MS: 19 yrs
    Type: Secondary Progressive
    Sensation: Moderate
    Overall: Moderate
    Cognition: severe
    Vision: mild
    Speech: moderate
    Swallowing: mild
    Upper limb: moderate
    Walking: moderate
  • LSK
  • by LSK
  • See LSK's full Daclizumab history
Purpose: MS (Multiple Sclerosis) (Started May 01, 2004)
Date Dosage Efficacy Side Effects Adherence Burden
Mar 01, 2006 60 mg Monthly Led_efficacy_2Led_efficacy_2Led_defaultLed_defaultSlight NoneNoneNoneNoneNone AlwaysAlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at allNot at all
  • Icon_thumb_off 0 helpful marks